Raymond James Financial
EBS icon

Raymond James Financial’s Emergent Biosolutions EBS Stock Holding History

Raymond James Financial’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$91.8K Sell
11,056
-17,225
-61% -$178K ﹤0.01% 5054
2025
Q4 		$350K Buy
+28,281
New +$303K ﹤0.01% 4479
2025
Q3 		– Sell
-8,328
Closed -$53.1K – 5468
2025
Q2 		$53.1K Buy
+8,328
New +$47.7K ﹤0.01% 5160

Other funds holding EBS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Raymond James Financial's EBS Position: Q1 2026 in Review

Raymond James Financial reduced its Emergent Biosolutions (EBS) stake by 61% in Q1 2026, selling an estimated $178K and leaving 11,056 shares worth $91.8K. The position accounts for ﹤0.01% of the portfolio, ranked #5054.

Raymond James Financial first reported a position in EBS in Q2 2025 and has held it in 3 quarters since. The position peaked at $350K in Q4 2025. 190 funds tracked by Wall St. Rank hold EBS as of Q1 2026.

  • Raymond James Financial held 11,056 shares of Emergent Biosolutions worth $91.8K as of Q1 2026.
  • Raymond James Financial sold 17,225 Emergent Biosolutions shares in Q1 2026, an estimated $178K.
  • Emergent Biosolutions made up ﹤0.01% of Raymond James Financial's portfolio in Q1 2026, its #5054 holding.
  • Raymond James Financial first reported a position in Emergent Biosolutions in Q2 2025 and has held it in 3 quarters since.
  • Raymond James Financial's Emergent Biosolutions position peaked at $350K in Q4 2025.
  • 190 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q1 2026.

Based on Raymond James Financial's 13F filing for Q1 2026, filed 14 May 2026.